6r2s: Difference between revisions
m Protected "6r2s" [edit=sysop:move=sysop] |
No edit summary |
||
| Line 3: | Line 3: | ||
<StructureSection load='6r2s' size='340' side='right'caption='[[6r2s]], [[Resolution|resolution]] 3.04Å' scene=''> | <StructureSection load='6r2s' size='340' side='right'caption='[[6r2s]], [[Resolution|resolution]] 3.04Å' scene=''> | ||
== Structural highlights == | == Structural highlights == | ||
<table><tr><td colspan='2'>[[6r2s]] is a 3 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6R2S OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6R2S FirstGlance]. <br> | <table><tr><td colspan='2'>[[6r2s]] is a 3 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human] and [http://en.wikipedia.org/wiki/Plavs Plavs]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6R2S OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6R2S FirstGlance]. <br> | ||
</td></tr><tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6r2s FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6r2s OCA], [http://pdbe.org/6r2s PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=6r2s RCSB], [http://www.ebi.ac.uk/pdbsum/6r2s PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=6r2s ProSAT]</span></td></tr> | </td></tr><tr id='gene'><td class="sblockLbl"><b>[[Gene|Gene:]]</b></td><td class="sblockDat">PVDR ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=126793 PLAVS])</td></tr> | ||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6r2s FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6r2s OCA], [http://pdbe.org/6r2s PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=6r2s RCSB], [http://www.ebi.ac.uk/pdbsum/6r2s PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=6r2s ProSAT]</span></td></tr> | |||
</table> | </table> | ||
== Function == | == Function == | ||
[[http://www.uniprot.org/uniprot/PVDR_PLAVS PVDR_PLAVS]] Binds to the human erythrocytes Duffy blood group determinant. | [[http://www.uniprot.org/uniprot/PVDR_PLAVS PVDR_PLAVS]] Binds to the human erythrocytes Duffy blood group determinant. | ||
<div style="background-color:#fffaf0;"> | |||
== Publication Abstract from PubMed == | |||
The most widespread form of malaria is caused by Plasmodium vivax. To replicate, this parasite must invade immature red blood cells through a process requiring interaction of the P. vivax Duffy binding protein (PvDBP) with its human receptor, the Duffy antigen receptor for chemokines. Naturally acquired antibodies that inhibit this interaction associate with clinical immunity, suggesting PvDBP as a leading candidate for inclusion in a vaccine to prevent malaria due to P. vivax. Here, we isolated a panel of monoclonal antibodies from human volunteers immunized in a clinical vaccine trial of PvDBP. We screened their ability to prevent PvDBP from binding to the Duffy antigen receptor for chemokines, and their capacity to block red blood cell invasion by a transgenic Plasmodium knowlesi parasite genetically modified to express PvDBP and to prevent reticulocyte invasion by multiple clinical isolates of P. vivax. This identified a broadly neutralizing human monoclonal antibody that inhibited invasion of all tested strains of P. vivax. Finally, we determined the structure of a complex of this antibody bound to PvDBP, indicating the molecular basis for inhibition. These findings will guide future vaccine design strategies and open up possibilities for testing the prophylactic use of such an antibody. | |||
Structural basis for inhibition of Plasmodium vivax invasion by a broadly neutralizing vaccine-induced human antibody.,Rawlinson TA, Barber NM, Mohring F, Cho JS, Kosaisavee V, Gerard SF, Alanine DGW, Labbe GM, Elias SC, Silk SE, Quinkert D, Jin J, Marshall JM, Payne RO, Minassian AM, Russell B, Renia L, Nosten FH, Moon RW, Higgins MK, Draper SJ Nat Microbiol. 2019 May 27. pii: 10.1038/s41564-019-0462-1. doi:, 10.1038/s41564-019-0462-1. PMID:31133755<ref>PMID:31133755</ref> | |||
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | |||
</div> | |||
<div class="pdbe-citations 6r2s" style="background-color:#fffaf0;"></div> | |||
== References == | |||
<references/> | |||
__TOC__ | __TOC__ | ||
</StructureSection> | </StructureSection> | ||
[[Category: Human]] | |||
[[Category: Large Structures]] | [[Category: Large Structures]] | ||
[[Category: Plavs]] | |||
[[Category: Barber, N M]] | [[Category: Barber, N M]] | ||
[[Category: Higgins, M K]] | [[Category: Higgins, M K]] | ||
Revision as of 09:23, 12 June 2019
The structure of Plasmodium vivax Duffy binding protein (PvDBP) bound to human antibody DB9The structure of Plasmodium vivax Duffy binding protein (PvDBP) bound to human antibody DB9
Structural highlights
Function[PVDR_PLAVS] Binds to the human erythrocytes Duffy blood group determinant. Publication Abstract from PubMedThe most widespread form of malaria is caused by Plasmodium vivax. To replicate, this parasite must invade immature red blood cells through a process requiring interaction of the P. vivax Duffy binding protein (PvDBP) with its human receptor, the Duffy antigen receptor for chemokines. Naturally acquired antibodies that inhibit this interaction associate with clinical immunity, suggesting PvDBP as a leading candidate for inclusion in a vaccine to prevent malaria due to P. vivax. Here, we isolated a panel of monoclonal antibodies from human volunteers immunized in a clinical vaccine trial of PvDBP. We screened their ability to prevent PvDBP from binding to the Duffy antigen receptor for chemokines, and their capacity to block red blood cell invasion by a transgenic Plasmodium knowlesi parasite genetically modified to express PvDBP and to prevent reticulocyte invasion by multiple clinical isolates of P. vivax. This identified a broadly neutralizing human monoclonal antibody that inhibited invasion of all tested strains of P. vivax. Finally, we determined the structure of a complex of this antibody bound to PvDBP, indicating the molecular basis for inhibition. These findings will guide future vaccine design strategies and open up possibilities for testing the prophylactic use of such an antibody. Structural basis for inhibition of Plasmodium vivax invasion by a broadly neutralizing vaccine-induced human antibody.,Rawlinson TA, Barber NM, Mohring F, Cho JS, Kosaisavee V, Gerard SF, Alanine DGW, Labbe GM, Elias SC, Silk SE, Quinkert D, Jin J, Marshall JM, Payne RO, Minassian AM, Russell B, Renia L, Nosten FH, Moon RW, Higgins MK, Draper SJ Nat Microbiol. 2019 May 27. pii: 10.1038/s41564-019-0462-1. doi:, 10.1038/s41564-019-0462-1. PMID:31133755[1] From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. References
|
| ||||||||||||||||